Aungst B J, Lam G, Shefter E
Biopharm Drug Dispos. 1985 Oct-Dec;6(4):413-21. doi: 10.1002/bdd.2510060407.
The disposition of the narcotic antagonist/analgesic nalbuphine after i.v., oral, and rectal dosing was evaluated in rats and dogs. In both species nalbuphine had high systemic clearance and low oral bioavailability as a result of extensive first-pass metabolism. Administration to a closed 2 cm length of rectum in rats resulted in complete bioavailability; first-pass metabolism was circumvented. However, the extent of first-pass metabolism increased when the dose was not restricted to the lower rectum. Rectal nalbuphine bioavailability in dogs from a solution or three suppository formulations was low and equivalent to oral bioavailability. This was probably because of upward spreading of the dose and subsequent first-pass metabolism. Sodium salicylate, which has been shown to improve rectal absorption of other drugs, did not affect nalbuphine bioavailability rectally.
在大鼠和狗身上评估了静脉注射、口服和直肠给药后麻醉拮抗剂/镇痛药纳布啡的处置情况。在这两个物种中,由于广泛的首过代谢,纳布啡具有高全身清除率和低口服生物利用度。给大鼠封闭的2厘米长直肠给药可导致完全生物利用度;首过代谢被规避。然而,当剂量不限于直肠下部时,首过代谢的程度会增加。狗从溶液或三种栓剂制剂中直肠给予纳布啡的生物利用度较低,且与口服生物利用度相当。这可能是由于剂量向上扩散以及随后的首过代谢。已证明可改善其他药物直肠吸收的水杨酸钠,对纳布啡的直肠生物利用度没有影响。